Table 1.

Pilot studies of trastuzumab and lapatinib in MBC

Trial	n	Arms	Setting	Overall response rate, %	PFS, months	OS, months
Slamon et al. [5]	234	trastuzumab + chemotherapy vs. chemotherapy	first line	50 vs. 32*	7.4 vs. 4.6*	25.1 vs. 20*
von Minckwitz et al. [17]	156	trastuzumab+capecitabine vs. capecitabine	beyond first line	48.1 vs. 27	8.2 vs. 5.6	25.5 vs. 20.4
Kaufman et al. [13]	207	anastrozole +trastuzumab vs. anastrozole	any line	20 vs. *7	4.8 vs. 2.4 *	28.5 vs. 23.9
Huober et al. [14]	92	letrozole +trastuzumab vs. letrozole	any line	27 vs. 13*	14.1 vs. 3.3	na
Di Leo et al [26]	579	lapatinib+ paclitaxel vs. paclitaxel	first line	63 vs. 38*	8.5 vs. 5.8*	24.0 vs. 19.8*
Cameron et al. [25]	399	lapatinib capecitabine vs. capecitabine	second line	32 vs. 17	5.5 vs. 4.2*	15.6 vs. 15.3
Blackwell et al. [37]	296	trastuzumab+lapatinib vs. lapatinib	after trastuzumab progression	10.3 vs. 6.9 *	12 vs. 8.1 weeks *	51.6 vs. 39 weeks
Johnston et al. [28]	44	letrozole + lapatinib vs. letrozole	first line	28 vs. 15*	8.2 vs. 3.0*	33.3 vs. 32.2

MBC = metastatic breast cancer, PFS = progression-free survival, OS = overall survival, na = not available.

^*Statistically significant with p < 0.05.